An overwhelming body of clinical evidence supports the primary benefits of mirabegron:
Results from large phase 3 phase 3 trials showed that oral mirabegron administration for 12 weeks reduced urinary frequency, urgency, and incontinence, and improved the health-related quality of life of patients.
A review of phase II, III, and IV studies has shown mirabegron to be safe and efficacious in the treatment of symptoms of overactive bladder.